An updated guideline on pharmacotherapy of obesity management in adults includes six new and seven revised recommendations, ...

Britain's blue-chip index climbed on Monday, led by healthcare and consumer shares, but losses in defence stocks ahead of ...

AstraZeneca PLC thrives with $54B revenue and 14 blockbusters in 2024, fueled by oncology and rare disease growth. Click for ...

A new study from the Gray Faculty of Medical and Health Sciences at Tel Aviv University may mark a breakthrough in the ...

Boehringer Ingelheim's bid to return to the oncology arena has been achieved with an FDA approval for Hernexeos, a new, ...

Anish Dsilva & Prof. Ariel Munitz A new study from the Gray Faculty of Medical and Health Sciences at Tel Aviv University may ...

Boehringer's Hernexeos is now FDA-approved for patients with HER2-positive NSCLC, bringing it into direct competition with ADC Enhertu.

The FTSE 100 index is set for a solid start to the week after US stock markets closed higher before the weekend. On Friday, ...

Sobi has completed the acquisition of AstraZeneca’s Synagis (palivizumab) for $1.5 billion in cash and shares, plus certain conditional payments. As part of the deal, first announced in August ...

Despite current headwinds like tariffs and patent expirations, I see long-term opportunity in top-tier pharmaceutical stocks ...